Nectero Medical Stock

www.necteromedical.com/Healthcare / BioTech & PharmaFounded: 2017

Nectero Medical is a biotechnology company that focuses on developing treatments intended for aneurysmal disease, which is a condition that causes patients to suffer from aneurysms. The company’s flagship product is the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System. Nectero EAST is designed for aneurysm management, particularly for small to medium-sized abdominal aortic aneurysms (AAA). It is an investigational system that strives to deliver pentagalloyl glucose directly into the aneurysmal wall with the goal of offering patients a minimally invasive alternative to traditional treatments.

Register To Buy and Sell Shares

For more details on financing and valuation for Nectero Medical, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Nectero Medical’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Nectero Medical.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Nectero Medical investors also invested in these private companies

Aphelion Capital
Boston Scientific
BioStar Capital
Cadence Healthcare Ventures
Park Partners Capital
SMO-Nectero

Team

Management Team

Jack Springer
Chief Executive Officer & President
Wenda Carlyle Ph.D
Chief Scientific Officer
Bryan Ziegler
Chief Financial Officer
Kelvin Ning
Senior Vice President – Technology
Kim Williams
Senior Vice President – Operations

Board Members

Alan Davis MD
BioStar Capital
Colin Morrison
Boston Scientific
Jack Springer
Nectero Medical
Zack Scott MD
Norwest Venture Partners

Frequently Asked Questions About Nectero Medical’s Stock

plusminus
Can you buy Nectero Medical’s stock?
Nectero Medical is not publicly traded on NYSE or NASDAQ in the U.S. To buy Nectero Medical’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Nectero Medical’s stock?
Yes, you can sell stock of a private company like Nectero Medical. Forge can help you sell your Nectero Medical stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Nectero Medical’s stock price?
Nectero Medical is a privately held company and therefore does not have a public stock price. However, you may access Nectero Medical’s private market stock price with Forge Data.
plusminus
What is Nectero Medical’s stock ticker symbol?
Nectero Medical does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Nectero Medical Announces Completion of $96M Series D Financing
Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, today announced the closing of its $96 million Series D financing round. Financing was led by Norwest Venture Partners, with large investments from Boston Scientific Corporation, BioStar Capital, Cadence Healthcare Ventures, Aphelion Capital and other firms.
Updated on: May 25, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.